idiopathic urticaria
Conditions
Interventions
Levocetirizine 10mg/day oral intake
Levocetirizine 5mg/day and chlorpheniramine maleate 4mg/day oral intake
Sponsors
Hiroshima university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult subject with spontaneous urticaria. Without reduction of daily urticaria scores being 4 or more in 3 days or more, after 7 days treatment with 5mg/day levocetirizine. Or with reductions of daily urticaria score 1 or more in 3 days or more, out of 7 days by taking lecocetirizine 5mg/day, and with daily urticarial score 4 or more in the last three days of the following 1 week treatment. Granted with written informed consent. Able to score daily urticaria activities according to the formatted urticaria diary. Agreed to re-visit the clinic for evaluation.
Exclusion criteria
Exclusion criteria: A history of drug allergy. Pregnant or lactating. Glaucoma, hyper intraocular pressure or inferior urinary tract obstruction. Hyperthyroidism or any cardiovascular disease. Stegnotic gastrointestinal ulceration or pylorus stegnosis. Taking central nervous depressant, alcohol, MAO inhibitor or anti-choline agent. Disease that discourages from taking anti- cholinergic drugs or antihistamines. High renal or liver damage. Decreased cognitive ability or comprehension. Histories of taking anti-leukotriene or H2-blocker within two weeks before agreement. Histories of taking steroids by strongest class topical application or injection within four weeks before agreement. Occupation driving or operating machines. Any patients evaluated as inadequate by physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of complete response | — |
Secondary
| Measure | Time frame |
|---|---|
| Days to be symptom free Change of symptom scores during treatments sleepiness | — |
Countries
Japan
Contacts
Public ContactKeiko Hanaoka
Hiroshima university hospital Department of Dermatology
Outcome results
None listed